All 1 tracked stories fall under one category: pharma. OSR Company is most often covered alongside Sinopharm, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about OSR Company
All 1 tracked stories fall under one category: pharma. OSR Company is most often covered alongside Sinopharm, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. The average consequence score is 6, matching the 6 beat baseline for this window. OSR Company appears in 1 tracked Biotech story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering OSR Company. Shared-story counts are live from our verified record — not editorial picks.
Woori IO, a subsidiary of OSR Company, has entered into a strategic Non-Disclosure Agreement (NDA) with Chinese pharmaceutical giant Sinopharm to explore commercialization opportunities in mainland China. The partnership also outlines a framework for collaboration on global multicenter clinical trials, signaling a major expansion for OSR's therapeutic pipeline into the world's second-largest pharmaceutical market.
